AI-generated summary
The authors compared near-infrared LED photobiomodulation (940 nm, delivered by a chest and abdomen vest) added to conventional treatment with conventional treatment alone in 30 patients with COVID-19. The authors report improvements in several cardiopulmonary measures and blood counts in the LED group, and a shorter hospital stay, and they conclude it may complement standard care.
- Participants
- 30
- Who or what was studied
- Patients with COVID-19 receiving hospital treatment, randomly divided into two equal groups of 15
- Wavelengths
- 940 nm
- Limits stated in the abstract
- The abstract describes a small sample of 30 patients and does not state how the groups were blinded or whether results were confirmed in larger trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 940 nm
- Power
- 6 W
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Photobiomodulation, Photobiomodulation therapy, Control group, Near-infrared, Inflammation, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.